It was surprising to find ibrutinib-treated CLL cells have the efficacy to inhibit CXCL13- and CXCL12- induced migration, which proves BTK signaling in cell migration to lymph nodes’ proliferation centers in CLL [35,36]. This evidence concerns the gene CXCL13 and B-cell chronic lymphocytic leukemia.